(Q44100761)

29 November 2017

Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? (English)

1 reference

29 November 2017

Dorne JL

1

1 reference

29 November 2017

Walton K

series ordinal

2

1 reference

29 November 2017

Slob W

series ordinal

3

1 reference

29 November 2017

Renwick AG

series ordinal

4

1 reference

29 November 2017

1 November 2002

1 reference

Food and Chemical Toxicology

29 November 2017

1 reference

29 November 2017

40

1 reference

29 November 2017

1633-1656

1 reference

29 November 2017

11

1 reference

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Food increases the bioavailability of propafenone

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Encainide disposition in patients with chronic cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Encainide disposition in patients with renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Quantification of metoprolol beta 2-adrenoceptor antagonism in asthmatic patients by pharmacokinetic-pharmacodynamic modelling

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Bioavailability of metoprolol in young adults and the elderly, with additional studies on the effects of metoclopramide and probanthine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Propafenone disposition in renal insufficiency and renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The influence of CYP2D6 activity on the kinetics of propafenone enantiomers in Chinese subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Stereoselective pharmacokinetics of propafenone and its major metabolites in healthy Chinese volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The role of S-mephenytoin 4'-hydroxylase in imipramine metabolism by human liver microsomes: a two-enzyme kinetic analysis of N-demethylation and 2-hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Absence of effect of stimulants on the phamacokinetics of desipramine in children

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Propafenone disposition kinetics in cardiac arrhythmia

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetic and pharmacodynamic properties of controlled release (CR/ZOK) metoprolol in healthy Oriental subjects: a comparison with conventional formulations of metoprolol and atenolol

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Enzyme induction in the elderly: Effect of rifampin on the pharmacokinetics and pharmacodynamics of propafenone

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Human variability in glucuronidation in relation to uncertainty factors for risk assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Influence of the defective metabolism of sparteine on its pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The genetic polymorphism of sparteine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Comparative pharmacokinetic profiles of metoprolol and chlorthalidone administered alone or in combination to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activity

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Risk evaluation: criteria arising from legal traditions and experience with quantitative risk assessment in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The metabolic fate of 2H-labelled propafenone in man

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Metoprolol in acute myocardial infarction. A pharmacokinetic and pharmacodynamic study

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pregnancy-induced increase in metoprolol metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Intravenous and oral propafenone for treatment of tachycardia in infants and children: pharmacokinetics and clinical response

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: Metoprolol, nadolol, and acebutolol

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Variability of beta-blocker pharmacokinetics in young volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Stereoselective disposition and pharmacologic activity of propafenone enantiomers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The effect of sertraline on the pharmacokinetics of desipramine and imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetics of metoprolol in healthy, elderly, non-smoking individuals after a single dose and two weeks of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Identification of propafenone metaboliser phenotype from plasma and urine excretion data.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Influence of hepatic dysfunction on the pharmacokinetics of propafenone.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Defective metabolism of metoprolol in poor hydroxylators of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a 14/190 metoprolol OROS system

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The pharmacokinetics and pharmacodynamics of metoprolol after conventional and controlled-release administration in combination with hydrochlorothiazide in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Investigation of xenobiotic metabolism by CYP2D6 and CYP2C19: importance of enantioselective analytical methods

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Regioselectivity and enantioselectivity of metoprolol oxidation by two variants of cDNA-expressed P4502D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetics of desipramine in Caucasian and Asian volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Data-derived safety factors for the evaluation of food additives and environmental contaminants

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Human variability and noncancer risk assessment- An analysis of the default uncertainty factor

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Inter- and intra-subject variability of metoprolol kinetics after intravenous administration.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Desipramine pharmacokinetics in Chinese and Caucasian volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Evidence for the activation of organophosphate pesticides by cytochromes P450 3A4 and 2D6 in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Influence of debrisoquin phenotype on the inducibility of propranolol metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Influence of hydroxychloroquine on the bioavailability of oral metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Phenobarbital induces the 2-hydroxylation of desipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The pharmacokinetics of venlafaxine when given in a twice-daily regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The effect of renal disease on the disposition of venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The influence of cimetidine on the disposition kinetics of the antidepressant venlafaxine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The concept of the acceptable daily intake: an historical review

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Polymorphic hydroxylation of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

The pharmacokinetic and pharmacodynamic interaction between propafenone and lidocaine.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6--a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Nonlinear kinetics of propafenone metabolites in healthy man

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetics of encainide in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Clinical pharmacology and antiarrhythmic efficacy of encainide in patients with chronic ventricular arrhythmias

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers--N-desisopropylation is mediated mainly by CYP1A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0278-6915%2802%2900117-5

7 January 2021

10.1016/S0278-6915(02)00117-5

Identifiers

DOI

1 reference

29 November 2017

1 reference